A short post says demand for GLP-1s, psychedelics and testosterone is meeting commercial interests, calling it a big shift.
Recap by typeshit. Post by Facebook on Facebook.
The chain says it is exploring concepts including grilled items aimed at GLP-1 users, a sign of how the drugs are shifting food businesses.
Ahead of results, Kalkine looks at how costly late-stage trials for Amgen's monthly obesity shot MariTide weigh on the outlook.
A beauty take that waves off pricey LA peptide and salmon sperm serums, saying better anti-aging habits are found closer to home.
LLY reached a fresh record while many tech stocks keep swinging, and the post weighs whether investors should take some profits.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Sales missed forecasts by about $33 million, but Lilly says demand more than tripled. Novo's Wegovy pill still holds roughly 75% of oral GLP-1 scripts.
Loading…